Kevin R. Thornal
Net Worth
Last updated:
What is Kevin R. Thornal net worth?
The estimated net worth of Mr. Kevin R. Thornal is at least $14,557,833 as of 15 Nov 2022. He owns shares worth $4,217,324 as insider, has earned $940,509 from insider trading and has received compensation worth at least $9,400,000 in Hologic, Inc..
What is the salary of Kevin R. Thornal?
Mr. Kevin R. Thornal salary is $1,880,000 per year as Division Pres of Diagnostic Solutions in Hologic, Inc..
How old is Kevin R. Thornal?
Mr. Kevin R. Thornal is 51 years old, born in 1974.
What stocks does Kevin R. Thornal currently own?
As insider, Mr. Kevin R. Thornal owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Hologic, Inc. (HOLX) | Division Pres of Diagnostic Solutions | 62,368 | $67.62 | $4,217,324 |
What does Hologic, Inc. do?
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Kevin R. Thornal insider trading
Hologic, Inc.
Mr. Kevin R. Thornal has made 3 insider trades between 2020-2022, according to the Form 4 filled with the SEC. Most recently he sold 12,490 units of HOLX stock worth $940,509 on 15 Nov 2022.
The largest trade he's ever made was exercising 16,869 units of HOLX stock on 10 Dec 2020. As of 15 Nov 2022 he still owns at least 62,368 units of HOLX stock.
Hologic key executives
Hologic, Inc. executives and other stock owners filed with the SEC:
- Mr. John M. Griffin (64) Gen. Counsel
- Mr. Kevin R. Thornal (51) Division Pres of Diagnostic Solutions
- Mr. Stephen P. MacMillan (61) Chairman, Chief Executive Officer & Pres
- Ms. Karleen M. Oberton (55) Chief Financial Officer